Display options
Cite
Vukojevic J, Milavić M, Perović D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487doi: 10.4103/1673-5374.320969.
Vukojevic, J., Milavić, M., Perović, D., Ilić, S., Čilić, A. Z., Đuran, N., Štrbe, S., Zoričić, Z., Filipčić, I., Brečić, P., Seiverth, S., & Sikirić, P. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural regeneration research, 17(3), 482-487. https://doi.org/10.4103/1673-5374.320969
Vukojevic, Jakša, et al. "Pentadecapeptide BPC 157 and the central nervous system." Neural regeneration research vol. 17,3 (2022): 482-487. doi: https://doi.org/10.4103/1673-5374.320969
Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022 Mar;17(3):482-487. doi: 10.4103/1673-5374.320969. PMID: 34380875; PMCID: PMC8504390.
Copy Download .nbib Format: NLM
Share it on

Neural Regen Res. 2022 Mar;17(3):482-487. doi: 10.4103/1673-5374.320969.

Pentadecapeptide BPC 157 and the central nervous system.

Neural regeneration research

Jakša Vukojevic, Marija Milavić, Darko Perović, Spomenko Ilić, Andrea Zemba Čilić, Nataša Đuran, Sanja Štrbe, Zoran Zoričić, Igor Filipčić, Petrana Brečić, Sven Seiverth, Predrag Sikirić

Affiliations

  1. Department of Pharmacology, Medical School, University of Zagreb, Zagreb, Croatia.
  2. Department of Pathology, Medical School, University of Zagreb, Zagreb, Croatia.
  3. University Clinical Hospital Center "Zagreb", Zagreb, Croatia.
  4. University Psychiatric Hospital "Vrap?e", Zagreb, Croatia.
  5. University Clinical Hospital Center "Sestre Milosrdnice", Zagreb, Croatia.
  6. Psychiatric Hospital "Sveti Ivan", Zagreb, Croatia.

PMID: 34380875 PMCID: PMC8504390 DOI: 10.4103/1673-5374.320969

Abstract

We reviewed the pleiotropic beneficial effects of the stable gastric pentadecapeptide BPC 157, three very recent demonstrations that may be essential in the gut-brain and brain-gut axis operation, and therapy application in the central nervous system disorders, in particular. Firstly, given in the reperfusion, BPC 157 counteracted bilateral clamping of the common carotid arteries-induced stroke, sustained brain neuronal damages were resolved in rats as well as disturbed memory, locomotion, and coordination. This therapy effect supports particular gene expression in hippocampal tissues that appeared in BPC 157-treated rats. Secondly, there are L-NG-nitro arginine methyl ester (L-NAME)- and haloperidol-induced catalepsy as well as the rat acute and chronic models of 'positive-like' schizophrenia symptoms, that BPC 157 counteracted, and resolved the complex relationship of the nitric oxide-system with amphetamine and apomorphine (dopamine agents application), MK-801 (non-competitive antagonist of the N-methyl-D-aspartate receptor) and chronic methamphetamine administration (to induce sensitivity). Thirdly, after rat spinal cord compression, there were advanced healing and functional recovery (counteracted tail paralysis). Likewise, in BPC 157 therapy, there is specific support for each of these topics: counteracted encephalopathies; alleviated vascular occlusion disturbances (stroke); counteracted dopamine disturbances (dopamine receptors blockade, receptors super sensitivity development, or receptor activation, over-release, nigrostriatal damage, vesicles depletion), and nitric oxide-system disturbances ("L-NAME non-responsive, L-arginine responsive," and "L-NAME responsive, L-arginine responsive") (schizophrenia therapy); inflammation reduction, nerve recovery in addition to alleviated hemostasis and vessels function after compression (spinal cord injury therapy). Thus, these disturbances may be all resolved within the same agent's beneficial activity, i.e., the stable gastric pentadecapeptide BPC 157.

Keywords: BPC 157; central nervous system; cytoprotection; injury; nitric oxide system; peptide; regeneration

Conflict of interest statement

None

References

  1. Neurosci Bull. 2019 Feb;35(1):167-170 - PubMed
  2. Eur J Pharmacol. 2016 Jan 15;771:211-9 - PubMed
  3. J Pharmacol Exp Ther. 1992 Oct;263(1):298-303 - PubMed
  4. Sci Rep. 2020 Oct 13;10(1):17078 - PubMed
  5. Regul Pept. 2010 Feb 25;160(1-3):33-41 - PubMed
  6. Inflammopharmacology. 2015 Dec;23(6):329-36 - PubMed
  7. PLoS One. 2015 Apr 21;10(4):e0123454 - PubMed
  8. World J Gastroenterol. 2017 Dec 28;23(48):8465-8488 - PubMed
  9. Inflammopharmacology. 2006 Dec;14(5-6):214-21 - PubMed
  10. World J Gastroenterol. 2017 Aug 7;23(29):5304-5312 - PubMed
  11. Life Sci. 2004 Dec 3;76(3):345-57 - PubMed
  12. Gen Psychiatr. 2019 Feb 23;32(1):e100026 - PubMed
  13. Eur J Pharmacol. 2016 Jun 15;781:83-91 - PubMed
  14. Oxid Med Cell Longev. 2019 Dec 30;2019:9084643 - PubMed
  15. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:177-81 - PubMed
  16. J Appl Physiol (1985). 2011 Mar;110(3):774-80 - PubMed
  17. Behav Brain Res. 2021 Jan 1;396:112919 - PubMed
  18. J Orthop Surg Res. 2019 Jul 2;14(1):199 - PubMed
  19. Br J Pharmacol. 2011 Oct;164(4):1162-94 - PubMed
  20. Drug Des Devel Ther. 2015 Apr 30;9:2485-99 - PubMed
  21. World J Gastrointest Pathophysiol. 2020 Mar 13;11(1):1-19 - PubMed
  22. Curr Pharm Des. 2014;20(7):1121-5 - PubMed
  23. Scand J Gastroenterol Suppl. 1986;125:92-6 - PubMed
  24. Inflammopharmacology. 2017 Aug;25(4):439-449 - PubMed
  25. Vascul Pharmacol. 2018 Jul;106:54-66 - PubMed
  26. Regul Pept. 2010 Feb 25;160(1-3):26-32 - PubMed
  27. Eur J Pharmacol. 1999 Aug 20;379(1):19-31 - PubMed
  28. Curr Pharm Des. 2018;24(18):1990-2001 - PubMed
  29. Prog Neurobiol. 1998 Nov;56(4):385-431 - PubMed
  30. Cell Tissue Res. 2019 Aug;377(2):153-159 - PubMed
  31. Emerg Med Int. 2020 May 27;2020:6805354 - PubMed
  32. Chin J Physiol. 1999 Sep 30;42(3):171-9 - PubMed
  33. J Physiol Pharmacol. 2018 Jun;69(3): - PubMed
  34. Curr Pharm Des. 2013;19(1):76-83 - PubMed
  35. Neuropsychopharmacology. 2002 Dec;27(6):980-92 - PubMed
  36. Brain Behav. 2020 Aug;10(8):e01726 - PubMed
  37. Eur J Pharmacol. 2007 Sep 10;570(1-3):212-21 - PubMed
  38. PLoS One. 2016 Sep 14;11(9):e0162590 - PubMed
  39. World J Hepatol. 2020 May 27;12(5):184-206 - PubMed
  40. Pharmacol Rev. 1992 Jun;44(2):151-347 - PubMed
  41. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct;20(7):1229-37 - PubMed
  42. Curr Pharm Des. 2020;26(25):2991-3000 - PubMed
  43. Gut Liver. 2020 Mar 15;14(2):153-167 - PubMed
  44. Molecules. 2014 Nov 19;19(11):19066-77 - PubMed
  45. Neurology. 2015 May 5;84(18):1894-903 - PubMed
  46. J Mol Med (Berl). 2017 Mar;95(3):323-333 - PubMed
  47. Curr Pharm Des. 2018;24(18):1947-1956 - PubMed
  48. Curr Pharm Des. 2018;24(18):1972-1989 - PubMed
  49. Spinal Cord. 2016 Nov;54(11):924-932 - PubMed
  50. Inflammopharmacology. 2017 May 17;: - PubMed
  51. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):827-32 - PubMed
  52. Curr Pharm Des. 2020;26(25):2971-2981 - PubMed
  53. Eur J Pharmacol. 2005 Apr 11;512(2-3):173-9 - PubMed
  54. Eur J Pharmacol. 2004 Sep 24;499(3):285-90 - PubMed
  55. Life Sci. 2017 Oct 1;186:66-79 - PubMed

Publication Types